228 related articles for article (PubMed ID: 23018565)
21. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
22. [Bullous pemphigoid and acquired haemophilia].
Kluger N; Navarro R; Pallure V; Guillot B
Ann Dermatol Venereol; 2011 May; 138(5):422-3. PubMed ID: 21570569
[No Abstract] [Full Text] [Related]
23. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
24. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
25. Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.
Campos-de-Magalhães M; Eduardo Brandão-Mello C; Lúcia Elias Pires M; Cecília da Fonseca Salgado M; Barcelo de Brito S; José de Almeida A
Hematology; 2011 Mar; 16(2):80-5. PubMed ID: 21418737
[TBL] [Abstract][Full Text] [Related]
26. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
27. [Immune coagulation disorders (excluding antiphospholipid syndrome].
Arai M
Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
[TBL] [Abstract][Full Text] [Related]
28. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
29. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
30. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
[TBL] [Abstract][Full Text] [Related]
31. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
32. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
34. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
35. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
36. Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission.
Porru G; Mura V; Piga M; Ibba V; Vacca A; Cauli A; Passiu G; Targhetta R; Marongiu F; Mathieu A
Clin Rheumatol; 2008 Dec; 27(12):1581-4. PubMed ID: 18827958
[TBL] [Abstract][Full Text] [Related]
37. Management of hemophilia patients with inhibitors.
Hedner U; Glazer S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
[TBL] [Abstract][Full Text] [Related]
38. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
39. Acquired haemophilia A in a woman with autoimmune hepatitis and systemic lupus erythematosus; review of literature.
Rezaieyazdi Z; Sharifi-Doloui D; Hashemzadeh K; Shirdel A; Mansouritorghabeh H
Blood Coagul Fibrinolysis; 2012 Jan; 23(1):71-4. PubMed ID: 22027758
[TBL] [Abstract][Full Text] [Related]
40. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus.
Trotta F; Bajocchi G; La Corte R; Moratelli S; Sun LY
Rheumatology (Oxford); 1999 Oct; 38(10):1007-9. PubMed ID: 10534554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
